Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSXKYG)

Drug Name
Gamma-Homolinolenic acid Drug Info
Synonyms
DGLA; BML3-B11; Ro 12-1989; Star GLA (GNC); Bishomo-gamma-linolenic acid; C 20:3 n-6; Dihomo-gamma-linolenic acid; Homo-gamma-linolenic acid; Homo-gamma-linolensaeure; Tona-lean 1000 CLA (Action Labs); Cis-8,11,14-Eicosatrienoic Acid; Eicosa-8Z,11Z,14Z-trienoic acid; All-cis-8,11,14-Eicosatrienoic acid; All-cis-8,11,14-icosatrienoic acid; All-cis-Eicosa-8,11,14-triensaeure; Cis,cis,cis-8,11,14-Eicosatrienoic acid; Cis-8,cis-11,cis-14-Eicosatrienoic acid; (8E,11E,14E)-8,11,14-Icosatrienoic acid; (8Z,11Z,14Z)-Icosatrienoic acid; (8Z,11Z,14Z)-icosa-8,11,14-trienoic acid; (Z,Z,Z)-8,11,14-Eicosatrienoate; (Z,Z,Z)-8,11,14-Eicosatrienoic acid; (Z,Z,Z)-8,11,14-Icosatrienoate; (Z,Z,Z)-8,11,14-Icosatrienoicacid; 20:3, n-6,9,12 all-cis; 8, 11, 14-eicosatrienoic acid; 8,11,14-Eicosatrienoate; 8,11,14-Eicosatrienoic acid; 8,11,14-Eicosatrienoic acid, (8Z,11Z,14Z)-(9CI); 8,11,14-Eicosatrienoic acid, (Z,Z,Z)-(8CI); 8,11,14-Icosatrienoate; 8,11,14-all-cis-Eicosatrienoic acid; 8c,11c,14c-Eicosatriensaeure; 8c,11c,14c-eicosatrienoic acid
Indication
Disease Entry ICD 11 Status REF
Malnutrition 5B50-5B71 Approved [1]
Therapeutic Class
Dietary supplement
Cross-matching ID
PubChem CID
5280581
ChEBI ID
CHEBI:53486
CAS Number
CAS 1783-84-2
TTD Drug ID
DMSXKYG
INTEDE Drug ID
DR1994

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [4]
Naproxen DMZ5RGV Bursitis Approved [5]
Mesalazine DMOL5IU Diverticulitis Approved [6]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [7]
Bromfenac DMKB79O Pain MG30-MG3Z Approved [8]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [9]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [10]
Piroxicam DMTK234 Osteoarthritis FA00-FA05 Approved [9]
Suprofen DMKXJZ7 Miosis LA11.62 Approved [11]
FENBUFEN DMXGDFK Arthritis FA20 Approved [12]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [13]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [14]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [13]
Diazepam DM08E9O Alcohol withdrawal Approved [13]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [13]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [13]
Nateglinide DMLK2QH Diabetic complication 5A2Y Approved [13]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [13]
Ketobemidone DMM3L6Z Pain MG30-MG3Z Approved [13]
Irbesartan DMTP1DC Diabetic kidney disease GB61.Z Approved [13]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Prostaglandin G/H synthase 2 (COX-2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [14]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [13]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [3]
Epanova DMHEAGL Hypertriglyceridemia 5C80.1 Approved [15]
Gamolenic acid DMQN30Z Allergy 4A80-4A85 Approved [3]
Omega-6-FA DMBWY8V N. A. N. A. Phase 3 [16]
Arachidonic Acid DMUOQZD Discovery agent N.A. Investigative [17]
alpha-linolenic acid DMY64HE Discovery agent N.A. Investigative [3]
Eicosadienoic acid DMVJK9W N. A. N. A. Investigative [3]
Icosapentum DMF1CM7 N. A. N. A. Investigative [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) DE492CE PGH2_HUMAN Substrate [3]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [3]

References

1 Treatment of rheumatoid arthritis with gammalinolenic acid. Ann Intern Med. 1993 Nov 1;119(9):867-73.
2 Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
3 Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
4 The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
5 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
6 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
8 Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
11 Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
12 Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
13 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
14 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
15 Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63.
16 Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
17 PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenet Genomics. 2011 Sep;21(9):607-13.